Covax Pharmaceuticals' offshore product, albumin paclitaxel, has been approved for market in the Dominican Republic.

On April 9th, according to Sinopharm's news, the company's anti-tumor product, the injectable paclitaxel Apexelsin, has made new progress in its internationalization journey in North America, and has been approved for listing by the Dominican Republic Ministry of Public Health and Social Welfare.